HC Wainwright Comments on Insmed’s Q1 Earnings (NASDAQ:INSM)

Insmed, Inc. (NASDAQ:INSM) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Insmed in a report released on Monday, February 23rd. HC Wainwright analyst A. Fein expects that the biopharmaceutical company will post earnings of ($1.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $230.00 price objective on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed’s Q2 2026 earnings at ($1.05) EPS, FY2028 earnings at $2.92 EPS and FY2029 earnings at $6.09 EPS.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The firm had revenue of $263.84 million during the quarter, compared to analysts’ expectations of $263.97 million. During the same quarter in the prior year, the company earned ($1.32) EPS. The business’s revenue for the quarter was up 152.6% on a year-over-year basis.

Several other equities analysts have also issued reports on INSM. Rothschild & Co Redburn set a $263.00 target price on Insmed in a report on Thursday, December 4th. The Goldman Sachs Group boosted their price objective on Insmed from $225.00 to $258.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. TD Cowen set a $241.00 target price on Insmed in a research report on Thursday, December 18th. Cantor Fitzgerald lifted their target price on Insmed from $216.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Finally, Bank of America set a $203.00 price target on shares of Insmed in a research report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Insmed currently has an average rating of “Buy” and a consensus price target of $207.86.

Insmed Trading Down 3.6%

NASDAQ:INSM opened at $159.03 on Tuesday. Insmed has a 52 week low of $60.40 and a 52 week high of $212.75. The firm has a 50-day moving average price of $164.37 and a two-hundred day moving average price of $164.24. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The firm has a market cap of $34.28 billion, a price-to-earnings ratio of -24.81 and a beta of 1.11.

Insider Activity

In other Insmed news, CEO William Lewis sold 19,215 shares of Insmed stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the completion of the sale, the chief executive officer directly owned 306,891 shares in the company, valued at $51,864,579. The trade was a 5.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the completion of the transaction, the insider directly owned 41,754 shares in the company, valued at $7,315,300.80. The trade was a 67.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 178,952 shares of company stock valued at $30,222,170 in the last three months. 3.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State of New Jersey Common Pension Fund D raised its position in Insmed by 8.5% during the second quarter. State of New Jersey Common Pension Fund D now owns 64,097 shares of the biopharmaceutical company’s stock valued at $6,451,000 after purchasing an additional 5,027 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of Insmed by 7.2% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 21,374 shares of the biopharmaceutical company’s stock valued at $2,151,000 after purchasing an additional 1,439 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Insmed by 12.5% during the 2nd quarter. Envestnet Asset Management Inc. now owns 365,827 shares of the biopharmaceutical company’s stock valued at $36,817,000 after buying an additional 40,520 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Insmed in the 2nd quarter worth approximately $22,574,000. Finally, Teacher Retirement System of Texas lifted its position in Insmed by 7.3% in the 2nd quarter. Teacher Retirement System of Texas now owns 49,013 shares of the biopharmaceutical company’s stock worth $4,933,000 after buying an additional 3,330 shares during the last quarter.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.